University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.K.E., S.R.C., T.L.B., L.M.F., J.J.E.).
Emory University, Atlanta, Georgia (J.E.R., V.C.M.).
Ann Intern Med. 2021 Sep;174(9):1197-1206. doi: 10.7326/M21-0065. Epub 2021 Jul 6.
BACKGROUND: Understanding advances in the care and treatment of adults with HIV as well as remaining gaps requires comparing differences in mortality between persons entering care for HIV and the general population. OBJECTIVE: To assess the extent to which mortality among persons entering HIV care in the United States is elevated over mortality among matched persons in the general U.S. population and trends in this difference over time. DESIGN: Observational cohort study. SETTING: Thirteen sites from the U.S. North American AIDS Cohort Collaboration on Research and Design. PARTICIPANTS: 82 766 adults entering HIV clinical care between 1999 and 2017 and a subset of the U.S. population matched on calendar time, age, sex, race/ethnicity, and county using U.S. mortality and population data compiled by the National Center for Health Statistics. MEASUREMENTS: Five-year all-cause mortality, estimated using the Kaplan-Meier estimator of the survival function. RESULTS: Overall 5-year mortality among persons entering HIV care was 10.6%, and mortality among the matched U.S. population was 2.9%, for a difference of 7.7 (95% CI, 7.4 to 7.9) percentage points. This difference decreased over time, from 11.1 percentage points among those entering care between 1999 and 2004 to 2.7 percentage points among those entering care between 2011 and 2017. LIMITATION: Matching on available covariates may have failed to account for differences in mortality that were due to sociodemographic factors rather than consequences of HIV infection and other modifiable factors. CONCLUSION: Mortality among persons entering HIV care decreased dramatically between 1999 and 2017, although those entering care remained at modestly higher risk for death in the years after starting care than comparable persons in the general U.S. population. PRIMARY FUNDING SOURCE: National Institutes of Health.
背景:了解成人艾滋病护理和治疗方面的进展以及仍然存在的差距,需要比较进入艾滋病护理的人与普通人群的死亡率差异。
目的:评估美国进入艾滋病护理的人群的死亡率高于普通美国人群的死亡率的程度,以及随着时间的推移这一差异的趋势。
设计:观察性队列研究。
地点:来自美国北美艾滋病队列协作研究和设计的 13 个地点。
参与者:1999 年至 2017 年间进入艾滋病毒临床护理的 82766 名成年人,以及根据美国国家卫生统计中心汇编的美国死亡率和人口数据,按日历时间、年龄、性别、种族/族裔和县在普通人群中匹配的一个子集。
测量:使用生存函数的 Kaplan-Meier 估计值估计 5 年全因死亡率。
结果:总体而言,进入艾滋病护理的人群的 5 年全因死亡率为 10.6%,而匹配的美国人群的死亡率为 2.9%,差异为 7.7(95%CI,7.4 至 7.9)个百分点。随着时间的推移,这一差异逐渐减小,从 1999 年至 2004 年进入护理的人群的 11.1 个百分点,减少到 2011 年至 2017 年进入护理的人群的 2.7 个百分点。
局限性:根据可用协变量进行匹配可能无法解释死亡率的差异,这些差异是由于社会人口因素而不是艾滋病毒感染和其他可改变因素的后果。
结论:1999 年至 2017 年期间,进入艾滋病护理的人群的死亡率大幅下降,尽管与普通美国人群相比,开始护理后几年进入护理的人群的死亡风险仍然略高。
主要资金来源:美国国立卫生研究院。
MMWR CDC Surveill Summ. 1999-4-16
Ann Intern Med. 2007-1-16
Open Forum Infect Dis. 2025-8-2
J Assoc Med Microbiol Infect Dis Can. 2024-12-19
J Antimicrob Chemother. 2025-7-1
JAMA Netw Open. 2025-5-1
Epigenomics. 2025-6
Viruses. 2024-6-23
Pharmaceuticals (Basel). 2024-7-4
JAMA Health Forum. 2024-5-3
MMWR Morb Mortal Wkly Rep. 2020-11-20
J Acquir Immune Defic Syndr. 2020-9-1
Clin Infect Dis. 2020-7-27
Front Public Health. 2019-4-24